Nanhua Bio Medicine Stock Working Capital
| 000504 Stock | 10.27 0.02 0.20% |
Nanhua Bio Medicine fundamentals help investors to digest information that contributes to Nanhua Bio's financial success or failures. It also enables traders to predict the movement of Nanhua Stock. The fundamental analysis module provides a way to measure Nanhua Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nanhua Bio stock.
The current year's Net Working Capital is expected to grow to about 212.6 M. The current year's Change In Working Capital is expected to grow to about 30.4 M. Nanhua | Working Capital |
Nanhua Bio Medicine Company Working Capital Analysis
Nanhua Bio's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Nanhua Bio Working Capital | 202.45 M |
Most of Nanhua Bio's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nanhua Bio Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Nanhua Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, Nanhua Bio Medicine has a Working Capital of 202.45 M. This is 118.24% lower than that of the Media sector and significantly higher than that of the Communication Services industry. The working capital for all China stocks is 86.3% higher than that of the company.
Nanhua Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nanhua Bio's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nanhua Bio could also be used in its relative valuation, which is a method of valuing Nanhua Bio by comparing valuation metrics of similar companies.Nanhua Bio is currently under evaluation in working capital category among its peers.
Nanhua Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.0455 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 3.09 B | ||||
| Shares Outstanding | 330.02 M | ||||
| Shares Owned By Insiders | 13.01 % | ||||
| Shares Owned By Institutions | 40.52 % | ||||
| Price To Book | 13.60 X | ||||
| Price To Sales | 26.78 X | ||||
| Revenue | 136.79 M | ||||
| Gross Profit | 127.36 M | ||||
| EBITDA | (38.19 M) | ||||
| Net Income | (28.17 M) | ||||
| Total Debt | 28.12 M | ||||
| Book Value Per Share | 0.75 X | ||||
| Cash Flow From Operations | 36.28 M | ||||
| Earnings Per Share | (0.12) X | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 3.33 B | ||||
| Total Asset | 771.38 M | ||||
| Retained Earnings | (531.1 M) | ||||
| Working Capital | 202.45 M | ||||
| Net Asset | 771.38 M |
About Nanhua Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nanhua Bio Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nanhua Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nanhua Bio Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nanhua Stock
Nanhua Bio financial ratios help investors to determine whether Nanhua Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanhua with respect to the benefits of owning Nanhua Bio security.